Menu Search
Equities

Aldeyra Therapeutics Inc

137:DUS

Aldeyra Therapeutics Inc

Actions
  • Price (EUR)3.67
  • Today's Change-0.056 / -1.50%
  • Shares traded700.00
  • 1 Year change-59.51%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 18:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

  • Revenue in USD (TTM)0.00
  • Net income in USD-30.01m
  • Incorporated2004
  • Employees10.00
  • Location
    Aldeyra Therapeutics Inc131 HARTWELL AVENUE, SUITE 320LEXINGTON 02421United StatesUSA
  • Phone+1 (781) 761-4904
  • Fax+1 (302) 636-5454
  • Websitehttps://www.aldeyra.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.